ReviewFrontiers in surgery2022
Prognostic significance of preoperative C-reactive protein to albumin ratio in non-small cell lung cancer patients: A meta-analysis.
Review in Frontiers in surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Comparison and validation of systemic immune-inflammation index, C-reactive protein/albumin ratio, and C-reactive protein-albumin-lymphocyte index for assessing disease activity in rheumatoid arthritis.Clinical rheumatology · 2026Article
- Comparative Prognostic Performance of CARWL and Naples Prognostic Score in Stage IIIC Non-Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy.Medical sciences (Basel, Switzerland) · 2026Article
- Association between C-reactive protein-to-albumin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study.BMC pulmonary medicine · 2026Article
- Predictive value of postoperative C-reactive protein-to-albumin ratio for severe complications following radical gastrectomy in gastric cancer patients.Frontiers in medicine · 2026Article
- Predictive value of systemic immune-inflammatory markers for lung cancer-associated cerebral infarction: a retrospective cohort study.American journal of cancer research · 2026Article
- Beyond Body Mass Index: The Impact of Height and Height-Normalised Weight on Overall Survival of Lung Cancer Undergoing Surgery.Journal of cachexia, sarcopenia and muscle · 2025Article
- The global immune-nutrition-inflammation index predicts pathological response and survival in esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy.Frontiers in nutrition · 2025Article
- Simple biomarkers based on CRP and albumin predict clinical outcomes in adult patients with T-cell acute lymphoblastic leukaemia.Frontiers in nutrition · 2025Article
- Platelet/Neutrophil Count Ratio (PNR) and Fibrinogen/Lymphocyte Count Ratio (FLR) Can Be Used as Predictive Indicators of Bone Metastasis in Non-Smoking Patients with Lung Cancer, but Not in Smoking Patients.International journal of general medicine · 2025Article
- Prognostic role of C-reactive protein to albumin ratio in lung cancer: An updated systematic review and meta-analysis.Chronic diseases and translational medicine · 2024Article
- Prognostic Value of the Noble and Underwood Score in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection.Journal of Cancer · 2024Article
- Interpretations of the Role of Plasma Albumin in Prognostic Indices: A Literature Review.Journal of clinical medicine · 2023Review
- Association Between Pretreatment White Blood Cell Count and Early Progression in Non-small Cell Lung Cancer.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to assess whether C-reactive protein to albumin ratio (CAR) is associated with the clinicopathology and prognosis of patients with non-small cell lung cancer (NSCLC) after surgery. Methods: Several literature databases were searched for eligible studies in English and Chinese published before September 1, 2022, according to the inclusion and exclusion criteria. The pooled odds ratios (ORs) with 95% confidence interval (CI) were calculated to assess the association of CAR in lung cancer with clinicopathological characteristics including age, sex, smoking status, lymph node metastasis, and American Association of Cancer (AJCC) stage. The pooled hazard ratios (HRs) with 95% CI were calculated to assess the association of CAR with prognosis in lung cancer. Publication bias was assessed using Egger's test. Results: Overall, 9 studies involving 3,359 NSCLC patients were included in this meta-analysis. The CAR was observed to be higher in males, smokers, and patients with lymph node metastasis and correlated with advanced AJCC stage but not with age. Moreover, a high CAR correlated with poor survival. No publication bias was observed in this meta-analysis. Conclusions: CAR was observed to be a significant biomarker for prognosis and associated with clinicopathological characteristics in patients with NSCLC after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.